Get the Stockscreener App
12.55
0.79%
-0.10
Pre-market:
12.70
0.15
+1.20%
Zevra Therapeutics Inc stock is traded at $12.55, with a volume of 1.87M.
It is down -0.79% in the last 24 hours and up +13.99% over the past month.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.
See More
Previous Close:
$12.65
Open:
$12.88
24h Volume:
1.87M
Relative Volume:
1.33
Market Cap:
$741.89M
Revenue:
$122.29M
Net Income/Loss:
$122.31M
P/E Ratio:
5.8266
EPS:
2.1539
Net Cash Flow:
$12.00M
1W Performance:
+3.80%
1M Performance:
+13.99%
6M Performance:
+53.61%
1Y Performance:
+37.46%
1-Day Range:
$12.37
$12.99
1-Week Range:
$12.37
$14.27
52-Week Range:
$7.16
$14.27
Zevra Therapeutics Inc Stock (ZVRA) Company Profile
Name
Zevra Therapeutics Inc
Sector
Industry
Phone
(888) 958-1253
Address
101 FEDERAL STREET, BOSTON
Compare ZVRA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZVRA
Zevra Therapeutics Inc
|
12.55 | 741.89M | 122.29M | 122.31M | 12.00M | 2.1539 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-26 | Initiated | BTIG Research | Buy |
| Jul-02-25 | Initiated | H.C. Wainwright | Buy |
| Jan-08-25 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-07-24 | Initiated | Guggenheim | Buy |
| Sep-24-24 | Initiated | JMP Securities | Mkt Outperform |
| Sep-24-24 | Reiterated | Maxim Group | Buy |
| Apr-02-24 | Reiterated | Maxim Group | Buy |
| Mar-12-24 | Initiated | William Blair | Outperform |
| Mar-17-23 | Initiated | Maxim Group | Buy |
View All
Zevra Therapeutics Inc Stock (ZVRA) Latest News
ZVRA Price Today: Zevra Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Zevra Therapeutics Q2 2025 Earnings Preview - MSN
ZVRA Stock Hits Its Highest Levels In Nearly 5 Years – What’s Driving This Sharp Rally Today? - Stocktwits
symbol__ Stock Quote Price and Forecast - CNN
ZVRA News | ZEVRA THERAPEUTICS INC (NASDAQ:ZVRA) - ChartMill
ZVRA Maintained by Canaccord Genuity -- Price Target Stays at $2 - GuruFocus
Zevra Therapeutics Is Maintained at Buy by Canaccord Genuity - Moomoo
A Quick Look at Today's Ratings for Zevra Therapeutics(ZVRA.US), With a Forecast Between $25 to $29 - Moomoo
Zevra’s Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition - The Manila Times
Press Release: Zevra's Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition - Moomoo
ZVRA Upgraded by Guggenheim -- Price Target Raised to $29 - GuruFocus
ZVRA Maintains Rating by Maxim Group -- Price Target Raised to $35.00 - GuruFocus
A Quick Look at Today's Ratings for Zevra Therapeutics(ZVRA.US), With a Forecast Between $25 to $34 - Moomoo
Zevra Therapeutics Is Maintained at Buy by Maxim Group - Moomoo
Maxim Group Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Raises Target Price to $35 - Moomoo
Guggenheim raises Zevra Therapeutics price target on patent extension - Investing.com UK
Guggenheim raises Zevra Therapeutics price target on patent extension By Investing.com - Investing.com Nigeria
ZVRA Reiterates by BTIG -- Price Target Raised to $27.00 - GuruFocus
Liquidity Mapping Around (ZVRA) Price Events - Stock Traders Daily
Is Zevra Therapeutics (ZVRA) Using MIPLYFFA Patent Extensions To Deepen Its Rare-Disease Moat? - Yahoo Finance
BTIG raises Zevra Therapeutics price target to $27 on patent filing - Investing.com Nigeria
ZVRA Maintains Buy Rating -- Price Target Raised to $29.00 by Ca - GuruFocus
BTIG raises Zevra Therapeutics price target to $27 on patent filing By Investing.com - Investing.com India
ZVRA stock hits its highest levels in nearly 5 years – what’s driving this sharp rally today? - MSN
ZVRA Maintains by Citizens -- Price Target Raised to $25.00 - GuruFocus
Zevra Therapeutics stock price target raised to $29 by Canaccord on patent extension - Investing.com South Africa
H.C. Wainwright reiterates Zevra Therapeutics stock rating on patent extension - Investing.com Nigeria
Citizens raises Zevra Therapeutics price target on patent exclusivity By Investing.com - Investing.com Nigeria
Citizens raises Zevra Therapeutics price target on patent exclusivity - Investing.com
Top Biotech Gainers: TNGX Hits New High, ALVO Moves Closer To FDA Approval, ZVRA, IDYA Turn Heads - RTTNews
ZVRA Maintained by Cantor Fitzgerald -- Price Target Raised to $34 - GuruFocus
Zevra Therapeutics (ZVRA) Files New Patent for Miplyffa - GuruFocus
Why is Zevra Therapeutics stock surging today? By Investing.com - Investing.com South Africa
Why is Zevra Therapeutics stock surging today? - Investing.com
ZVRA Stock ‘Way Undervalued’? Analyst Sees 117% Upside After Patent Extends Exclusivity Till 2041 For Sole Approved Drug - Yahoo Finance
Zevra Therapeutics extends MIPLYFFA exclusivity to 2041 - Yahoo Finance
Zevra Therapeutics Announces Orange Book Listing of U.S. Patent Strengthening Exclusivity for MIPLYFFA - The Manila Times
Zevra moves to list rare disease drug MIPLYFFA in FDA Orange Book - Stock Titan
Zevra Therapeutics Inc Stock (ZVRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):